Cover Page. The handle holds various files of this Leiden University dissertation.

Similar documents
Set the stage: Genomics technology. Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands

Maria João Silva H. Louro 1, T. Borges 2, J. Lavinha 1, J.M. Albuquerque 1

The effect of REACH implementation on genotoxicity and carcinogenicity testing Jan van Benthem

ICH Topic S1B Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals. Step 5

1 Institute for In Vitro Sciences, 2 The Procter & Gamble Co., 3 MatTek Corporation

New Technologies for Predicting Genotoxic Risk in Humans

A novel toxicogenomics-based approach to categorize. (non-)genotoxic carcinogens

DISCUSSION GROUP 3. Mechanism of carcinogenicity. EFSA Scientific Colloquium on Acrylamide carcinogenicity, 22/23 May

Session 2: Biomarkers of epigenetic changes and their applicability to genetic toxicology

VICH GL23: Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing

Genotoxicity of formaldehyde in vitro and in vivo. Günter Speit

Glyphosate Hazard and Risk Assessment: A Comparison of the Approaches of Two International Agencies

Genotoxicity Testing Strategies: application of the EFSA SC opinion to different legal frameworks in the food and feed area

The potential impact of toxicogenomics on modern chemical risk assessment 3-MCPD and 3-MCPD fatty acid esters as examples

Society of Toxicology Carcinogenesis Specialty Section (CSS)

IPA Advanced Training Course

Risk-prediction modelling in cancer with multiple genomic data sets: a Bayesian variable selection approach

Thresholds of Toxicological Concern

Epigenetics and Toxicology

Prof. dr. J.P. Groten Professor of Combination Toxicology at Wageningen University Global head drug safety Europe at MSD, Oss

Opinion on. Classification of Musk ketone

Chapter 3. Toxicity and the Factors That Modify Toxic Responses

OECD QSAR Toolbox v.4.2. An example illustrating RAAF scenario 6 and related assessment elements

Glyphosate and Cancer Buying Science

HOW GOOD ARE VALIDATED METHODS TO PREDICT TOXICITY OF DIFFERENT TYPES OF SUBSTANCES AND PRODUCTS?

ToxStrategies, Inc. and Summit Toxicology

Dose Response Approaches for Nuclear Receptor Mediated Modes of Action Workshop Preliminary Report

Cover Page. The handle holds various files of this Leiden University dissertation.

Proof of principle tests confirm genotoxic potential of RF-EMF

Table of Validated and Accepted Alternative Methods

Introduction to Cancer Biology

Tuberous Sclerosis Complex Research Program

Section 5.3: Preclinical safety data

Liposarcoma*Genome*Project*

Rethinking Approaches To Low Dose Extrapolation for Environmental Health Risk Assessment

Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology

EPIGENOMICS PROFILING SERVICES

ENVIRONMENTAL REGULATIONS AND STANDARD SETTING Health Based Standards: Oncology - Luc Hens

Can Coatings Primer and Safety Assessment: Communicating Evidence of Absence

Chapter 1. Introduction

Genome Stability Department of Physiology

MATERIAL SAFETY DATA SHEET

Hexavalent Chromium Oral Reference Dose

ACRYLAMIDE - EU Summary of Activities

A Quantitative Toxicogenomics Assay for Highthroughput. and Mechanistic Genotoxicity. Assessment and Screening of Environmental

Validation of Genetic Determinants of Skeletal Diseases. Dr Kasia Piróg (Newcastle University)

Cancer and Gene Regulation

NexGen Risk Assessment

APPROVED: 23 November 2016 AMENDED: 7 April EFSA Scientific Colloquium 22. Epigenetics and Risk Assessment: Where do we stand?

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

Toxicological Characterisation of Dermal Exposure to DBPs by an In Vitro Skin Model

Childhood Leukemia and ELF Fields Progress Report

CONTENTS NOTE TO THE READER... 1

Cancer Epigenetics: Methods And Protocols (Methods In Molecular Biology) READ ONLINE

Review of Danish EPA List of EDCs

Biotransformation-induced toxicity. Challenges in drug design M. Matilde Marques

Regulation of Genotoxic and Carcinogenic Impurities in

Threshold Establishment and Rationale. Douglas J Ball, MS, DABT Research Fellow Pfizer Worldwide R&D

Epigenetic Regulation of Health and Disease Nutritional and environmental effects on epigenetic regulation

alternative short-chain fluorinated product technology

Morphogens: What are they and why should we care?

MATERIAL SAFETY DATA SHEET

Cancer Problems in Indonesia

Epigenetics. Jenny van Dongen Vrije Universiteit (VU) Amsterdam Boulder, Friday march 10, 2017

Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment 1

Predictive Assays in Radiation Therapy

LOW DOSES OF RADIATION REDUCE RISK IN VIVO

Mutagenesis. David M. DeMarini, Ph.D. University of North Carolina at Chapel Hill.

Contribution to the European Commission s Public Consultation on. 15 January 2015

12 HEALTH RISK ASSESSMENT

Section H. Case Study: Risk Assessment Issues Associated with Chloroform

Cover Page. The handle holds various files of this Leiden University dissertation.

Adapted from: Google Maps. Available at (Last accessed: September 26 th 2011)

Metabolomics: quantifying the phenotype

Lecture -2- Environmental Biotechnology

Genetic Toxicology. Toxicology for Industrial and Regulatory Scientists

BUNDESINSTITUT FÜR RISIKOBEWERTUNG

University of Bristol Cancer Research Fund Report

Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment 1

Title: The fate of bone marrow-derived cells carrying a polycystic kidney disease mutation in the genetically normal kidney

5. Summary of Data Reported and Evaluation

MANGANESE & HEALTH: A BALANCE OF STORIES

The Biology and Genetics of Cells and Organisms The Biology of Cancer

Cell Cycle In Development (Results And Problems In Cell Differentiation) READ ONLINE

Abstract. Patricia G. Melloy*

The Comet Assay Tails of the (Un)expected

Part 2. Chemical and physical aspects

Approaches used to evaluate mechanistic data for the Report on Carcinogens (RoC) by the National Toxicology Program (NTP)

The Application of Genomic Technologies to Benzene Litigation

Summary & conclusion

Certificate of Advanced Studies in Personalized Molecular Oncology

ESTIMATION OF TOXICITY TO HUMANS

Chromosome Effects in Oncology Workers Handling Chemotherapy Agents and Implications for Safe Handling

ASSESSING ENDOCRINE DISRUPTING SUBSTANCES

Report of a Workshop on Dose-Response Approaches for Nuclear Receptor- Mediated Modes of Action

UvA-DARE (Digital Academic Repository) Marfan syndrome: Getting to the root of the problem Franken, Romy. Link to publication

How to overcome limitations of new approach methodologies in the context of regulatory science

Pailin Group Executive Search Assistant Investigator: Cancer Genetics, Epigenetics and Biomarkers Dallas, TX

An epigenetic approach to understanding (and predicting?) environmental effects on gene expression

p53 and Apoptosis: Master Guardian and Executioner Part 2

Transcription:

Cover Page The handle http://hdl.handle.net/1887/43419 holds various files of this Leiden University dissertation. Author: Schaap, M.M. Title: The use of transcriptomics data in detecting non-genotoxic carcinogens Issue Date: 2016-10-04

Chapter 6 General discussion

Chapter 6 General discussion and concluding remarks Cancer hazard identification of chemical substances is essential to predict possible risks for human health. The carcinogenic potential of chemicals can be identified through animal studies, whereby tumor formation is indicative of chemical carcinogenicity. However, animal studies to predict toxicological endpoints such as carcinogenicity are under severe societal pressure. Therefore, development and use of adequate in vitro tests becomes more and more important. As described in Chapter 1, in vitro tests predicting carcinogenic potential of chemicals mainly comprise genotoxicity assays. These assays have the disadvantage that many false positive results are produced, i.e. chemicals that test positive in vitro but appear to be negative in vivo. Since a positive result in vitro usually triggers further testing in vivo, these false positive results unnecessarily increase the number of follow up in vivo tests. Additionally, by definition carcinogenic chemicals that do not directly induce DNA-damage, i.e. the so called non-genotoxic carcinogens, go undetected in these tests. Only a limited number of in vitro assays focusing on the identification of non-genotoxic carcinogens is available and not each assay is considered adequate to detect carcinogenic potentials. The goal of the research described in this thesis was to improve testing strategies for cancer hazard assessment. The first objective was to develop an in vitro approach to assess genotoxicity, with the intention to reduce the number of false positive results produced in the in vitro genotoxicity assays commonly used. The second objective was to improve the identification of non-genotoxic carcinogens by using a toxicogenomics approach based on recognizing modes of action. In this final chapter the results are summarized, discussed and directions for future research are given. Reducing the number of false positive results Assessment of the genotoxic potential of a chemical substance often requires more than one in vitro test as most in vitro genotoxicity tests do not detect simultaneously (structural and numerical) chromosomal aberrations as well as gene mutations. We demonstrated that chemicals inducing structural chromosomal aberrations or gene mutations can be both detected by using proliferating primary mouse hepatocytes obtained from pur288 LacZ plasmidbased transgenic mice (Chapter 2). Furthermore, this study showed that features 144

General discussion required for reliable genotoxicity testing as described by Kirkland et al. (Kirkland et al. 2008), such as cells being p53 and DNA repair proficient and metabolically competent, were all present in the proliferating primary mouse hepatocytes. The main question that remained was: does the method described in Chapter 2 lead to a reduction in the number of false positive test results? Recent data (Luijten et al. 2016) showed that a selected set of chemicals known to produce false positive test results were negative under test conditions described in Chapter 2. Taken together, this testing system is a promising tool for genotoxic hazard assessment. However, there are also a few issues to discuss. Most notably, the test system is based on primary mouse hepatocytes and thus still requires animals. Next, the LacZ reporter assay is quite laborious and not every laboratory is able to perform this assay. Nevertheless, under certain circumstances it might be worthwhile to consider the LacZ reporter assay to assess genotoxic potential. Next to the LacZ reporter assay other innovative genotoxicity tests have been developed. Examples are the human reconstructed skin micronucleus (RSMN) assay (Curren et al. 2006; Mun et al. 2009), the GreenScreen HC genotoxicity assay (Birrell et al. 2010; Hastwell et al. 2006; Walmsley and Tate 2012) and the ToxTracker assay (Hendriks et al. 2012). These assays all have their pros and cons and have been described more extensively in Chapter 1. What they have in common is the goal to reduce the high number of false positive in vitro results, thereby contributing to a reduction in animal testing. Future studies, including more extensive validation studies, will provide insight into how these assays, including the LacZ reporter assay, can contribute to a robust, relevant and efficient assessment of genotoxic hazard. Recognizing modes of action of non-genotoxic carcinogens by a toxicogenomics approach The second objective was to improve the identification of non-genotoxic carcinogens by using a toxicogenomics approach based on recognizing overlap in gene expression patterns of non-genotoxic carcinogens having the same mode of action. Studies focusing on this objective are described in Chapter 3, Chapter 4 and Chapter 5. Two different ways to analyze toxicogenomics data were investigated: a supervised and an unsupervised approach. The major difference between these two approaches is the knowledge requirement on modes of action of non-genotoxic carcinogens, which is necessary for the supervised approach 6 145

Chapter 6 but not for the unsupervised approach. In the supervised approach (Chapter 3), a set of overlapping genes was selected and assessed for its significance for a pair of chemicals known to have a similar mode of action. This method requires substantial knowledge on modes of action of chemicals. To become applicable for risk assessment purposes, extensive databases are required covering many features of chemicals having different modes of action. The problem with this supervised approach is that chemicals are forced into boxes, which ignores the fact that chemicals might have several additional modes of action (see also Chapter 5). The second (unsupervised) method developed within this thesis to recognize modes of action of non-genotoxic carcinogens was called the comparison approach (Chapter 3 and Chapter 4). Gene sets consisting of the most significantly regulated genes upon chemical exposure are compared to the gene sets of other (test) chemicals under the same experimental setup. Chemicals that are known to have a similar mode of action are, through this approach, linked to each other. Furthermore, additional information on adjunct modes of action can be obtained through a convincing match with other chemicals. This unsupervised method of exploring gene expressing profiles is, compared to the supervised approach, more objective as it can be applied without having specific knowledge on the mode(s) of action on beforehand. As such, it is better applicable in test strategies for hazard identification. In Chapter 3 and Chapter 4 chemicals were tested at a single concentration based on cytotoxicity data. By applying identical concentration selection criteria for all chemicals, it was assumed that overt cytotoxic effects could be avoided while testing conditions applied would still be sufficiently robust to detect (carcinogenic) modes of action. However, it was found that changes in expression profiles varied from virtually no response to a change in expression levels of almost 25 percent of all detectable genes. It was therefore recommended to test multiple concentrations per chemical. To investigate the added value of this recommendation a proof of principle experiment was performed using the non-genotoxic carcinogens Cyclosporin A and Tacrolimus, both immune suppressants (Chapter 5). Performing the gene expression profiling study in primary mouse hepatocytes at a single concentration did not result in a common profile. However, by using a concentration range overlapping gene sets for Cyclosporin A and Tacrolimus were observed. Common alterations in gene expression nicely reflected pathways known to be triggered by these 146

General discussion chemicals and, as such, demonstrated the biological significance of this adapted approach. Another major advantage of the comparison approach is that it not only detects non-genotoxic carcinogens more efficiently, but that it is also applicable to other chemicals having different modes of action. Indeed, in Chapter 4 it was demonstrated that genotoxic chemicals, because of similarity in gene expression profiles, can be categorized. Position of to the introduced approaches in the carcinogenicity test strategies Both the genotoxicity assay and the comparison approach, were developed with the intention to improve risk assessment of chemicals in terms of assessing genotoxic and carcinogen potential. Although these approaches are not ready yet for implementation in risk assessment, a new test strategy for cancer hazard assessment is proposed in which both approaches as developed within this thesis are integrated (Figure 1). It is proposed that the first tier in carcinogenicity testing comprises the use of existing data complemented with in silico approaches such as (Q)SARs and read-across (see Chapter 1). Mutant frequency assessment through the LacZ reporter assay using proliferating primary hepatocytes (PPH in Figure.1) to detect (reliable) gene mutations as well as chromosomal aberrations is added to the second tier, i.e. the in vitro genotoxicity tests. Positive results still require in vivo confirmation, but the assumption is that, through implementation of the LacZ reporter assay, the number of false positives, i.e. positive in vitro but negative in vivo, will be significantly reduced. Test chemicals negative in the LacZ reporter assay and in other in vitro and in vivo genotoxicity tests will be subjected to the comparison approach, which is now integrated in the last tier of the proposed test strategy. Through comparison of gene expression profiles of (non-genotoxic carcinogenic) chemicals insights will be obtained on possible modes of action that are known to be involved in carcinogenesis. Considering the fact that more and more knowledge on modes of action in carcinogenesis will become available, it seems to be highly likely that the comparison approach will trigger dedicated further testing. Future prospective In the described studies within this thesis, the primary cell system used consisted of primary mouse hepatocytes. This cell system has multiple advantages, with its capacity to actively perform biotransformation being most important. 6 147

Chapter 6 However, not all chemicals will be detected using mouse hepatocytes, and therefore other cell systems should also be considered to detect (other) carcinogenic modes of action. As shown in Chapter 4, mouse embryonic stem cells complement primary hepatocytes. Next to this, the introduction of human derived cell systems will be advantageous, in this way that it may better reflect the human situation. Overall, multiple cell systems will be required for robust and reliable prediction of modes of action of chemicals. Figure 1 Proposed scheme for carcinogenicity testing. Abbreviations: PPH proliferating primary hepatocytes, MLA mouse lymphoma assay, MN micronucleus test, CA chromosome aberration test. The mutation frequency assessment in proliferating primary hepatocytes (PPH) is added to the battery of in vitro genotoxicity tests. Next, the comparison approach is in corporated in the fourth tier to further investigate the carcinogenic mode of action of non-genotoxic chemicals. For hazard identification of unknown chemicals omic technologies, like transcriptomics, metabolomics and proteomics, become more and more important. Data derived from these studies can be used in different ways. One 148

General discussion approach is biomarker identification to categorize chemicals into different chemical classes, e.g. genotoxic versus non-genotoxic. However, with the knowledge that non-genotoxic carcinogens act through different mechanisms, a mode of action based approach becomes increasingly important. Assuming that such an approach is based on comparisons to existing data, extensive libraries of expression profiles are needed which can be used as reference when obtaining knowledge on modes of action of unknown (carcinogenic) chemicals. Ideally, such libraries consist of gene expression profiles of chemicals derived from various in vitro systems at multiple concentrations. In addition, other profiles, like proteome, metabolome, DNA methylation, or mirna, can be registered as well. An example of such a library is the comparative toxicogenomics database (Davis et al. 2015). This database exists for ten years already and it comprises over 10,000 chemicals, 40,000 genes and various species. Within this database it is possible to connect chemicals, genes/proteins, diseases, taxa, Gene Ontology (GO) annotations and pathways. Additionally, the knowledge on epigenetic mechanisms involved in tumor formation is increasing (Greally and Jacobs 2013; Herceg et al. 2013). It is therefore reasonable to assume that assays for detecting changes in DNA methylation, histone modification and mirna associated with non-genotoxic carcinogens will become available in the coming years. Also, rapid evolvement of advanced sequencing approaches might offer the next step in hazard identification of chemicals. In the meantime it is worthwhile to further develop the mechanismbased comparison approach. 6 149

Chapter 6 References Birrell L, Cahill P, Hughes C, Tate M, Walmsley RM (2010) GADD45a-GFP GreenScreen HC assay results for the ECVAM recommended lists of genotoxic and non-genotoxic chemicals for assessment of new genotoxicity tests. Mutat Res 695(1-2):87-95 Curren RD, Mun GC, Gibson DP, Aardema MJ (2006) Development of a method for assessing micronucleus induction in a 3D human skin model (EpiDerm). Mutat Res 607(2):192-204 Davis AP, Grondin CJ, Lennon-Hopkins K, et al. (2015) The Comparative Toxicogenomics Database s 10th year anniversary: update 2015. Nucleic Acids Res 43(Database issue):d914-20 Greally JM, Jacobs MN (2013) In vitro and in vivo testing methods of epigenomic endpoints for evaluating endocrine disruptors. ALTEX 30(4):445-71 Hastwell PW, Chai LL, Roberts KJ, et al. (2006) High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat Res 607(2):160-75 Hendriks G, Atallah M, Morolli B, et al. (2012) The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. Toxicol Sci 125(1):285-98 Herceg Z, Lambert MP, van Veldhoven K, et al. (2013) Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation. Carcinogenesis 34(9):1955-67 Kirkland D, Kasper P, Muller L, Corvi R, Speit G (2008) Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: a follow-up to an ECVAM workshop. Mutat Res 653(1-2):99-108 Mun GC, Aardema MJ, Hu T, et al. (2009) Further development of the EpiDerm 3D reconstructed human skin micronucleus (RSMN) assay. Mutat Res 673(2):92-9 Walmsley RM, Tate M (2012) The GADD45a-GFP GreenScreen HC assay. Methods Mol Biol 817:231-50 150